Login to Your Account



Kosan, Pfizer In $250M Deal For Motilin Agonist Program

By Karen Pihl-Carey


Thursday, December 21, 2006
As Kosan Biosciences Inc. focuses on its cancer therapeutics, it licensed out its motilin agonist program to Pfizer Inc. in a worldwide deal worth up to $250 million in up-front and milestone payments. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription